KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Non-Current Assets: 2017-2024

Historic Other Non-Current Assets for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $594.0 million.

  • Moderna's Other Non-Current Assets fell 4.68% to $530.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $530.0 million, marking a year-over-year decrease of 4.68%. This contributed to the annual value of $594.0 million for FY2024, which is 22.45% down from last year.
  • As of FY2024, Moderna's Other Non-Current Assets stood at $594.0 million, which was down 22.45% from $766.0 million recorded in FY2023.
  • In the past 5 years, Moderna's Other Non-Current Assets registered a high of $988.0 million during FY2022, and its lowest value of $11.0 million during FY2020.
  • Over the past 3 years, Moderna's median Other Non-Current Assets value was $766.0 million (recorded in 2023), while the average stood at $782.7 million.
  • In the last 5 years, Moderna's Other Non-Current Assets soared by 2,047.83% in 2022 and then decreased by 22.47% in 2023.
  • Yearly analysis of 5 years shows Moderna's Other Non-Current Assets stood at $11.0 million in 2020, then surged by 318.18% to $46.0 million in 2021, then skyrocketed by 2,047.83% to $988.0 million in 2022, then fell by 22.47% to $766.0 million in 2023, then declined by 22.45% to $594.0 million in 2024.